B of A Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice TargetHot
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
B of A Securities analyst Tazeen Ahmad maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $908 to $1030.
B of A Securities analyst Tazeen Ahmad maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $908 to $1030.
